Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

This study has been terminated.
(Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.)
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00455572
First received: April 2, 2007
Last updated: August 7, 2014
Last verified: August 2014